Recombinant antibody against toxic fractions of cobra venom

Ali Nazari,1,* Maedeh samianifard,2 Hadi rabiee,3

1. Biochemistry Dept. , Razi Vaccine and Serum Research Institute
2. Biochemistry Dept. , Razi Vaccine and Serum Research Institute
3. Razi vaccine and serum research institute



Snake-bitten poisoning depending on species is a serious risk in varying area like as our country, iran. at the moment horse antisera against snake venom, mono or polyvalent is the best approach to the treatment of humans who were envenomated. the aim of this study was to separate strong binders from an antibody phage library, comprises over 100 million different antibody fragments cloned in an ampicillin resistant phagemid vector and transformed into tg1 e. coli cells.


Selection and polyvalent of recombinant antibodies were carried out against two purified toxic fractions of naja naja oxiana venom. the reaction between antibodies and their targets took place in mono and snake-bitten phage elisa signifying some good binders. restriction enzyme analysis of selected phagemid clones showed a complete fragment of 717 bp for antibodies. two purified soluble antibodies clones, f3b4 and f4h1, were able to inhibit the toxic activity of crude venom partially.


Overall, purification of toxic fractions from naja naja oxiana venom successfully was done and phage antibody display provided a highly efficient method for the isolation of specific immunological reagents. the selected antibodies had the potential to neutralise of crude venom at the calculated level. the selected antibodies are in progress for more characterization.


Consequently, phage display technology might provide an alternative scheme to treat snake bites than the traditional serotherapy.


Recombinant antibody- venom - antivenom- naja oxiana